NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Hi Umibe.
Disclosure: I have absolutely no expert credentials at all in this field!
I perhaps should have made it clearer that I was just offering an opinion.

Some of the trial subjects may have some remaining tumor tissue available, which could be used for micro-array analysis.
So it's not impossible that such tests could be undertaken.

I believe this is the 23 patient trial that led them on to the path of this line of research. Trouble is, it is the same 23 patients, who received a TLR agonist, either Imiquimod or Poly ICLC, or no agonist. Which muddies the data.

It's just my hunch from the blinded interim results, that the findings of the 23 patient study have not been born out in the P3.
But on the bright side, I think we are seeing some across the board efficacy, which probably includes those with a pro-neural signature, whereas in the 23 patient study they did no better than matched controls.

http://clincancerres.aacrjournals.org/content/17/6/1603

Table 1 which is accessible from the page linked gives a breakdown of all patient characteristics including gene expression profile (for most) and whether an agonist was used.